Immunology Biosimilars Market Expected To Reach $15.3 Billion By 2030 As Growth Accelerates At 12.8% CAGR
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Immunology Biosimilars Market Expected To Reach $15.3 Billion By 2030 At 12.8% CAGR
The immunology biosimilars market has experienced significant expansion over the past few years. Its value is projected to rise from $8.35 billion in 2025 to $9.45 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.2%. Several factors drove this growth in the historical period, including the elevated expense of original biologics, a restricted supply of biosimilar options, a higher incidence of autoimmune conditions, greater integration of biologics into hospital and clinical settings, and rigorous regulatory approvals for biosimilars.
The immunology biosimilars market is anticipated to undergo robust expansion over the coming years. Forecasts indicate it will reach a valuation of $15.3 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.8%. Key factors fueling this growth during the forecast period include the creation of more sophisticated biosimilar molecules, an increase in homecare and outpatient treatment alternatives, greater regulatory alignment, heightened patient knowledge and acceptance, and the expansion of both online and hospital pharmacy distribution networks. Prominent trends shaping this period include a higher uptake of monoclonal antibody biosimilars, greater utilization of fusion protein biosimilars, the broadening of recombinant protein therapies, a growing market for interferon-based treatments, and improved access to cost-effective immunology therapies.
Download A Free Sample Report For Comprehensive Market Insights:
Immunology Biosimilars Market Growth Drivers: What Factors Are Accelerating Expansion?
The anticipated expansion of the immunology biosimilars market is being driven by the rising frequency of chronic immunological diseases. These conditions represent long-term disorders where the immune system either attacks the body’s own tissues or fails to function correctly. This increase can be attributed to the growing number of people suffering from persistent immune system dysfunctions that demand ongoing treatment, careful disease monitoring, and sustained medical support. By offering cost-effective and efficient treatment options, immunology biosimilars play a crucial role in managing such diseases; they facilitate long-term care, enhance patient access to necessary therapies, and help regulate immune system irregularities. As an example, data from November 2023 published by the Multiple Sclerosis International Federation (MSIF), a UK-based global nonprofit focusing on MS research and advocacy, indicated that roughly 2.9 million individuals around the world were affected by multiple sclerosis that year. Consequently, the growing prevalence of chronic immunological conditions is fueling progress within the immunology biosimilars market.
Immunology Biosimilars Market Segments: Where Are The Largest Growth Opportunities?
The immunology biosimilars market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Fusion Proteins, Recombinant Proteins, Interferons, Other Biosimilar Immunomodulators
2) By Disease: Inflammatory Bowel Disease, Arthritis, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End User: Hospitals, Clinics, Homecare Settings, Ambulatory Surgical Centers (ASCs)
Subsegments:
1) By Monoclonal Antibodies: Anti-Tumor Necrosis Factor Agents, Anti-Interleukin-6 Agents, Anti-Cluster of Differentiation 20 Agents, Anti-Interleukin-12/23 Agents, Other Monoclonal Antibodies
2) By Fusion Proteins: Etanercept Biosimilars, Other Fusion Protein Biosimilars
3) By Recombinant Proteins: Recombinant Human Insulin, Recombinant Human Growth Hormone, Recombinant Human Erythropoietin, Other Recombinant Protein Biosimilars
4) By Interferons: Interferon Alpha, Interferon Beta, Interferon Gamma
5) By Other Biosimilar Immunomodulators: Interleukin Inhibitors, Janus Kinase Inhibitors, Other Immunomodulatory Biosimilars
Immunology Biosimilars Market Trends: What Is Shaping Future Industry Growth?
Key players within the immunology biosimilars sector are prioritizing next-generation innovations, including potential interchangeability designations, improved formulations offering better stability, and novel delivery mechanisms, all aimed at delivering more affordable and effective treatment pathways for patients. The anticipated interchangeability designation indicates that the biosimilar is likely to satisfy regulatory requirements, enabling pharmacy-level substitution for the reference biologic product without requiring prescriber approval. As an example, Sandoz Group AG, a pharmaceutical firm headquartered in Switzerland, introduced Pyzchiva (ustekinumab-ttwe) in February 2025, a biosimilar referencing Stelara, intended for chronic autoimmune disorders such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Developed in collaboration with Samsung Bioepis Co. Ltd., a South Korean biopharmaceutical entity, this launch demonstrates Sandoz’s dedication to increasing the availability of immunology biosimilars by delivering a cost-effective, patient-focused therapy featuring various dosing choices, prolonged stability, and a distinctive capacity for re-refrigeration following initial cold storage.
Immunology Biosimilars Market Major Participants And Competitive Dynamics
Major companies operating in the immunology biosimilars market are Pfizer Inc., Novartis AG, Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Gedeon Richter Plc, Celltrion Inc., Biocon Ltd., Innovent Biologics Inc., Biocad, Mabion S.A.
Access The Complete Immunology Biosimilars Market Report:
Immunology Biosimilars Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the immunology biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunology biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
